Mark Stump
Novartis
7 Papers
10 Citations
Mark Stump is an academic researcher from Novartis. The author has contributed to research in topics: Tumor suppressor gene & Biology. The author has an hindex of 5, co-authored 7 publications. Previous affiliations of Mark Stump include Harvard University.
Chat about Author
Papers
Project DRIVE: A Compendium of Cancer Dependencies and Synthetic Lethal Relationships Uncovered by Large-Scale, Deep RNAi Screening
E. Robert McDonald,Antoine de Weck,Michael R. Schlabach,Eric Billy,Konstantinos J. Mavrakis,Gregory R. Hoffman,Dhiren Belur,Deborah Castelletti,Elizabeth Frias,Kalyani Gampa,Javad Golji,Iris Kao,Li Li,Philippe Megel,Thomas A. Perkins,Nadire Ramadan,David A. Ruddy,Serena J. Silver,Sosathya Sovath,Mark Stump,Odile Weber,Roland Widmer,Jianjun Yu,Kristine Yu,Yingzi Yue,Dorothee Abramowski,Elizabeth Ackley,Rosemary Barrett,Joel Berger,Julie L. Bernard,Rebecca Billig,Saskia M. Brachmann,Frank Buxton,Roger Caothien,Justina X. Caushi,Franklin Chung,Marta Cortes-Cros,Rosalie deBeaumont,Clara Delaunay,Aurore Desplat,William Duong,Donald A. Dwoske,Richard S. Eldridge,Ali Farsidjani,Fei Feng,JiaJia Feng,Daisy Flemming,William C. Forrester,Giorgio G. Galli,Zhenhai Gao,François Gauter,Veronica Gibaja,Kristy Haas,Marc Hattenberger,Tami Hood,Kristen Hurov,Zainab Jagani,Mathias Jenal,Jennifer Johnson,Michael D. Jones,Avnish Kapoor,Joshua M. Korn,Jilin Liu,Qiumei Liu,Shumei Liu,Yue Liu,Alice T. Loo,Kaitlin J. Macchi,Typhaine Martin,Gregory McAllister,A. B. Meyer,Sandra Mollé,Raymond Pagliarini,Tanushree Phadke,Brian Repko,Tanja Schouwey,Frances Shanahan,Qiong Shen,Christelle Stamm,Christine Stephan,Volker M. Stucke,Ralph Tiedt,Malini Varadarajan,Kavitha Venkatesan,Alberto C. Vitari,Marco Wallroth,Jan Weiler,Jing Zhang,Craig Mickanin,Vic E. Myer,Jeffery A. Porter,Albert Lai,Hans Bitter,Emma Lees,Nicholas Keen,Audrey Kauffmann,Frank Stegmeier,Francesco Hofmann,Tobias Schmelzle,William R. Sellers +99 more
TL;DR: A large-scale RNAi screen is conducted in which viability effects of mRNA knockdown were assessed for 7,837 genes using an average of 20 shRNAs per gene in 398 cancer cell lines, outlining the classes of cancer dependency genes and their relationships to genetic, expression, and lineage features.
632
Disordered methionine metabolism in MTAP/CDKN2A-deleted cancers leads to dependence on PRMT5.
Konstantinos J. Mavrakis,E. Robert McDonald,Michael R. Schlabach,Eric Billy,Gregory R. Hoffman,Antoine deWeck,David A. Ruddy,Kavitha Venkatesan,Jianjun Yu,Gregg McAllister,Mark Stump,Rosalie deBeaumont,Samuel B. Ho,Yingzi Yue,Yue Liu,Yan Yan-Neale,Guizhi Yang,Fallon Lin,Hong Yin,Hui Gao,D. Randal Kipp,Songping Zhao,Joshua T. McNamara,Elizabeth R. Sprague,Bing Zheng,Ying Lin,Young Shin Cho,Justin Gu,Kenneth Crawford,David N. Ciccone,Alberto C. Vitari,Albert Lai,Vladimir Capka,Kristen Hurov,Jeffery A. Porter,John A. Tallarico,Craig Mickanin,Emma Lees,Raymond Pagliarini,Nicholas Keen,Tobias Schmelzle,Francesco Hofmann,Frank Stegmeier,William R. Sellers +43 more
TL;DR: By interrogating data from a large-scale short hairpin RNA–mediated screen across 390 cancer cell line models, it is found that the viability of MTAP-deficient cancer cells is impaired by depletion of the protein arginine methyltransferase PRMT5.
445
Maximizing the Efficacy of MAPK-Targeted Treatment in PTENLOF/BRAFMUT Melanoma through PI3K and IGF1R Inhibition.
Barbara Herkert,Audrey Kauffmann,Sandra Mollé,Christian Schnell,Thomas Ferrat,Hans Voshol,Janina Juengert,Hélène Erasimus,Grégory Marszalek,Malika Kazic-Legueux,Eric Billy,David A. Ruddy,Mark Stump,Daniel Guthy,Mitko Ristov,Keith Calkins,Sauveur-Michel Maira,William R. Sellers,Francesco Hofmann,Michael N. Hall,Saskia M. Brachmann +20 more
TL;DR: These findings provide a strong rationale for testing combinations of panPI3K, PI3Kβ + IGF1R, and MAPK pathway inhibitors in PTEN(LOF)/BRAF(MUT) melanoma patients to achieve maximal response.
Gene Expression Ratios Lead to Accurate and Translatable Predictors of DR5 Agonism across Multiple Tumor Lineages.
Anupama Reddy,Joseph D. Growney,Nicholas S. Wilson,Caroline Emery,Jennifer Johnson,Rebecca Ward,Kelli A. Monaco,Joshua M. Korn,John Monahan,Mark Stump,Felipa A. Mapa,Christine D. Wilson,Janine L. Steiger,Jebediah Ledell,Richard Rickles,Vic E. Myer,Seth Ettenberg,Robert Schlegel,William R. Sellers,Heather Huet,Joseph Lehar +20 more
TL;DR: The approach of using gene expression ratios presents a robust and novel method for constructing translatable biomarkers of compound response, which can also probe the underlying biology of treatment response.